## Bone-RADS™ v2023 Assessment Categories and Scoring System

Release Date: February 2023

<table>
<thead>
<tr>
<th>Bone-RADS Score</th>
<th>Risk Category</th>
<th>Description</th>
<th>Management</th>
</tr>
</thead>
</table>
| 0               | Incompletely Characterized | Risk cannot be adequately predicted  
Point Total = N/A  
Example: Lucent lesions of the axial skeleton such as scapula, spine, or pelvis | • Further workup is necessary  
• Additional radiographic views or cross-sectional imaging for further evaluation |
| 1               | Very Low Risk          | Pathognomonic benign bone lesion  
Point Total = 1–2  
Example: Non-ossifying fibroma, osteoid osteoma | If asymptomatic, consider work up to be complete vs annual surveillance to ensure expected stability  
If symptomatic or change in clinical presentation, consider advanced imaging and orthopedic oncology referral for treatment of benign tumor |
| 2               | Low Risk               | Asymptomatic geographic lytic lesion without suspicious periosteal reaction or deep endosteal erosion  
Point Total = 3–4  
Example: Enchondroma, giant cell tumor, aneurysmal bone cyst | Short interval (3-6 month) surveillance to ensure stability  
Consider advanced imaging to assess tumor composition and possibly biopsy to confirm benignity if needed  
Consider orthopedic oncology referral for surveillance or treatment of benign tumor |
| 3               | Intermediate Risk      | Geographic lytic lesion in a patient with primary malignancy elsewhere  
Point Total = 5–6  
Example: Geographic, but ill-defined lytic lesion | Orthopedic oncology referral for probable biopsy and treatment planning  
Recommend advanced imaging such as CT, MRI, or bone scan for further characterization |
| 4               | High Risk              | Malignant until proven otherwise  
Geographic lytic lesion with aggressive periosteal reaction or soft tissue mass  
Point Total ≥ 7  
Example: Non-geographic osteolytic lesion | Orthopedic oncology referral for recommended biopsy and treatment planning  
Advanced imaging for tumor staging including additional sites of disease |

### Add All Points to Determine Bone-RADS Score Level and Management

<table>
<thead>
<tr>
<th>MARGINS</th>
<th>PERIOSTEAL REACTION</th>
<th>ENDOSTEAL EROSION</th>
<th>PATHOLOGICAL FRACTURE</th>
<th>SOFT TISSUE MASS</th>
<th>KNOWN PRIMARY CANCER</th>
<th>TOTAL POINTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA 1</td>
<td>None 0</td>
<td>Mild 0</td>
<td>If YES = 2</td>
<td>If YES = 2</td>
<td>If YES = 2</td>
<td></td>
</tr>
<tr>
<td>IB 3</td>
<td>Non-aggressive 2</td>
<td>Moderate 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II 5</td>
<td>Aggressive 4</td>
<td>Deep 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIIA-C 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© 2023 American College of Radiology® | All rights reserved